Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Teva Seeking FDA OK to Make Generic Version of Firdapse for LEMS

Teva Pharmaceuticals is seeking authorization from federal regulators in the U.S. to produce and sell a generic version of Firdapse (amifampridine), an approved treatment for Lambert-Eaton myasthenic syndrome (LEMS). Firdapse, marketed by Catalyst Pharmaceuticals, was approved by the U.S. Food and Drug Administration in 2018 as the…

Catalyst’s Revenue From Firdapse Tops $50M in 3rd Quarter 2022

Catalyst Pharmaceuticals earned $57.2 million in the third quarter of 2022 from sales of Firdapse (amifampridine), its treatment for Lambert-Eaton myasthenia syndrome (LEMS). According to Catalyst, this represents an all-time high net revenue from Firdapse, a 59.3% year-over-year increase and a gain of 7.8% compared with the…

Updated Criteria May Help Diagnosis of Cancer-related Diseases: Study

Recently updated criteria to identify cancer-associated diseases like Lambert-Eaton myasthenic syndrome (LEMS) are highly specific and sensitive at detecting these conditions, a recent study reports. The study, “Real-world application of the updated diagnostic criteria for paraneoplastic neurological syndromes,” was published in the Journal of Neuroimmunology.